Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lanreotide Acetate

FDA-approved product (solution, subcutaneous), marketed as Lanreotide Acetate, Somatuline Depot.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lanreotide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Carcinoid syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Somatostatin and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA68.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lanreotide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lanreotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

    NCT00216398 · start 2004-06

    Registered record
    Registry ID
    NCT00216398
    Conditions
    Acromegaly
    Interventions
    Lanreotide (Autogel formulation)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-06
    Completion
    2006-06-22
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionLanreotide (Autogel formulation)
    PhasePhase 4
    Registry statusCompleted

  • Somatuline Autogel: Acromegaly Self/Partner Injection Study

    NCT00149188 · start 2004-02

    Registered record
    Registry ID
    NCT00149188
    Conditions
    Acromegaly
    Interventions
    Lanreotide (Autogel formulation)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-02
    Completion
    2005-08-24
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionLanreotide (Autogel formulation)
    PhasePhase 4
    Registry statusCompleted

  • Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

    NCT00627796 · start 2003-01

    Registered record
    Registry ID
    NCT00627796
    Conditions
    Acromegaly
    Interventions
    Lanreotide-Autogel 120 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    2007-12
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionLanreotide-Autogel 120 mg
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

    NCT00234572 · start 2000-05

    Registered record
    Registry ID
    NCT00234572
    Conditions
    Acromegaly
    Interventions
    Lanreotide (Autogel formulation)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2000-05
    Completion
    2003-01-03
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionLanreotide (Autogel formulation)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Cardiovascular Outcome After Surgery or Somatostatin Analogues

    NCT00615004 · start 1997-01

    Registered record
    Registry ID
    NCT00615004
    Conditions
    Acromegaly
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1997-01
    Completion
    2007-12
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted